![Targeted therapy achieves durable objective responses Phase I/II LIBRETTO-001 trial](https://d2jx2rerrg6sh3.cloudfront.net/image.axd?picture=2016%2f6%2fCancer_cell_attacked_by_lymphocytes-Juan_Gaertner-590_f02db7247e67499f8e792d0b3c3a72b3-150x125.jpg)
Targeted therapy achieves durable objective responses Phase I/II LIBRETTO-001 trial
For patients with non-small cell lung cancers (NSCLC) marked by RET gene fusions, the targeted therapy selpercatinib was well tolerated and achieved durable objective responses, or tumor shrinkage, in the majority of participants in the Phase I/II LIBRETTO-001 trial, according to researchers from The University of Texas MD Anderson Cancer Center.
No hay comentarios:
Publicar un comentario